Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

It is all in the factors: effects of cognitive remediation on symptom dimensions.

Cella M, Reeder C, Wykes T.

Schizophr Res. 2014 Jun;156(1):60-2. doi: 10.1016/j.schres.2014.03.032. Epub 2014 Apr 24.

PMID:
24768130
2.

The impact of cognitive remediation on psychiatric symptoms of schizophrenia.

Bark N, Revheim N, Huq F, Khalderov V, Ganz ZW, Medalia A.

Schizophr Res. 2003 Oct 1;63(3):229-35.

PMID:
12957702
3.

The role of negative symptoms in the context of cognitive remediation for schizophrenia.

Farreny A, Aguado J, Ochoa S, Haro JM, Usall J.

Schizophr Res. 2013 Oct;150(1):58-63. doi: 10.1016/j.schres.2013.08.008. Epub 2013 Aug 29.

PMID:
23993864
4.

Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients.

Gharaeipour M, Scott BJ.

Schizophr Res. 2012 Dec;142(1-3):165-70. doi: 10.1016/j.schres.2012.09.018. Epub 2012 Oct 25.

PMID:
23102691
5.

REPYFLEC cognitive remediation group training in schizophrenia: Looking for an integrative approach.

Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J.

Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035. Epub 2012 Sep 25.

PMID:
23017827
6.

Complementary group Metacognitive Training (MCT) reduces delusional ideation in schizophrenia.

Moritz S, Veckenstedt R, Bohn F, Hottenrott B, Scheu F, Randjbar S, Aghotor J, Köther U, Woodward TS, Treszl A, Andreou C, Pfueller U, Roesch-Ely D.

Schizophr Res. 2013 Dec;151(1-3):61-9. doi: 10.1016/j.schres.2013.10.007. Epub 2013 Oct 30.

PMID:
24183707
7.

Role of learning potential in cognitive remediation: Construct and predictive validity.

Davidson CA, Johannesen JK, Fiszdon JM.

Schizophr Res. 2016 Mar;171(1-3):117-24. doi: 10.1016/j.schres.2016.01.044. Epub 2016 Jan 29.

8.

Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis.

Cella M, Preti A, Edwards C, Dow T, Wykes T.

Clin Psychol Rev. 2017 Mar;52:43-51. doi: 10.1016/j.cpr.2016.11.009. Epub 2016 Nov 28. Review.

9.

Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study.

Klingberg S, Herrlich J, Wiedemann G, Wölwer W, Meisner C, Engel C, Jakobi-Malterre UE, Buchkremer G, Wittorf A.

J Nerv Ment Dis. 2012 Jul;200(7):569-76. doi: 10.1097/NMD.0b013e31825bfa1d.

PMID:
22759932
10.

d-Cycloserine augmentation of cognitive remediation in schizophrenia.

Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E, Goff DC.

Schizophr Res. 2014 Mar;153(1-3):177-83. doi: 10.1016/j.schres.2014.01.016. Epub 2014 Jan 30.

11.

Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial.

Puig O, Penadés R, Baeza I, De la Serna E, Sánchez-Gistau V, Bernardo M, Castro-Fornieles J.

J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):859-68. doi: 10.1016/j.jaac.2014.05.012. Epub 2014 Jun 21.

PMID:
25062593
12.

Cognitive behavioural treatment of negative symptoms in schizophrenia patients: study design of the TONES study, feasibility and safety of treatment.

Klingberg S, Wittorf A, Herrlich J, Wiedemann G, Meisner C, Buchkremer G, Frommann N, Wölwer W.

Eur Arch Psychiatry Clin Neurosci. 2009 Nov;259 Suppl 2:S149-54. doi: 10.1007/s00406-009-0047-8.

PMID:
19876673
13.

Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study.

Klingberg S, Wölwer W, Engel C, Wittorf A, Herrlich J, Meisner C, Buchkremer G, Wiedemann G.

Schizophr Bull. 2011 Sep;37 Suppl 2:S98-110. doi: 10.1093/schbul/sbr073.

14.

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

Marder SR, Davis JM, Chouinard G.

J Clin Psychiatry. 1997 Dec;58(12):538-46. Erratum in: J Clin Psychiatry 1998 Apr;59(4):200.

PMID:
9448657
15.

Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.

Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Köther U, Woodward TS, Treszl A, Menon M, Schneider BC, Pfueller U, Roesch-Ely D.

JAMA Psychiatry. 2014 Oct;71(10):1103-11. doi: 10.1001/jamapsychiatry.2014.1038.

PMID:
25103718
16.

Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.

Stefanovics EA, Krystal JH, Rosenheck RA.

Compr Psychiatry. 2014 May;55(4):887-95. doi: 10.1016/j.comppsych.2014.01.014. Epub 2014 Jan 31.

PMID:
24602497
17.

Converting positive and negative symptom scores between PANSS and SAPS/SANS.

van Erp TG, Preda A, Nguyen D, Faziola L, Turner J, Bustillo J, Belger A, Lim KO, McEwen S, Voyvodic J, Mathalon DH, Ford J, Potkin SG, Fbirn.

Schizophr Res. 2014 Jan;152(1):289-94. doi: 10.1016/j.schres.2013.11.013. Epub 2013 Dec 11.

18.

A randomized study of cognitive remediation for forensic and mental health patients with schizophrenia.

Ahmed AO, Hunter KM, Goodrum NM, Batten NJ, Birgenheir D, Hardison E, Dixon T, Buckley PF.

J Psychiatr Res. 2015 Sep;68:8-18. doi: 10.1016/j.jpsychires.2015.05.013. Epub 2015 May 30.

PMID:
26228394
19.

Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms.

Moritz S, Veckenstedt R, Randjbar S, Vitzthum F, Woodward TS.

Psychol Med. 2011 Sep;41(9):1823-32. doi: 10.1017/S0033291710002618. Epub 2011 Jan 28.

PMID:
21275083
20.

Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.

Kane JM, Yang R, Youakim JM.

Schizophr Res. 2012 Mar;135(1-3):116-22. doi: 10.1016/j.schres.2011.11.006. Epub 2011 Dec 16.

PMID:
22178084

Supplemental Content

Support Center